Skip to content Skip to navigation

Celgene Thalomid and Revlimid Antitrust Settlement

Share
Active: 
Open
Settlement Structure: 
Case Summary: 

Celgene Corporation is paying $55 million to settle antitrust class actions about its drugs Thalomid and Revlimid. The complaints alleged that the company acted to keep generics of the drugs off the market for a time, forcing consumers to pay more for the drugs than they would have with open market competition.

Docket Number: 
2:14-cv-06997
Company: 
Celgene
Class Period: 
Thursday, August 1, 2019
Filing Deadline: 
Monday, December 30, 2019
Objection Deadline: 
Monday, December 2, 2019
Exclusion Deadline: 
Monday, December 2, 2019
Final Approval Hearing: 
Monday, January 6, 2020
Bottle of Revlimid Pills